Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

SITAGLIPTIN AND METFORMIN HYDROCHLORIDE

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

Standard Dose
500MG;EQ 50MG BASE
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Prescription
Summary

Approval overview SITAGLIPTIN AND METFORMIN HYDROCHLORIDE is listed in Drugs@FDA under application 202388 (ANDA).

Marketing status: Prescription Active ingredient METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE Form and strength TABLET;ORAL - 500MG;EQ 50MG BASE Sponsor SANDOZ Submission history Latest submission status date: 2025-12-02 00:00:00.

Structured Monograph

Clinical summary

Approval overview SITAGLIPTIN AND METFORMIN HYDROCHLORIDE is listed in Drugs@FDA under application 202388 (ANDA). Marketing status: Prescription Active ingredient METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE Form and strength TABLET;ORAL - 500MG;EQ 50MG BASE Sponsor SANDOZ Submission history Latest submission status date: 2025-12-02 00:00:00. Submission type: ORIG.

Monitoring

  • • Review priority: STANDARD
  • • Marketing status: Prescription

Interaction Notes

  • No interaction notes stored yet.
SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE) | Drug Monograph | MedicHelpline